v3.20.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
REVENUES:    
Product revenue $ 29,206,249 $ 16,842,456
License revenue 142,834 142,834
Total Revenues 29,349,083 16,985,290
OPERATING EXPENSES:    
Cost of product revenue (exclusive of amortization expense shown below) 39,504,238 42,194,635
Research and development 2,343,848 3,926,120
Plasma center operating expenses 2,169,629 7,805,619
Amortization of intangibles 844,938 844,938
Selling, general and administrative 25,910,757 22,502,922
Total operating expenses 70,773,410 77,274,234
LOSS FROM OPERATIONS (41,424,327) (60,288,944)
OTHER INCOME (EXPENSE):    
Interest income 800,785 195,403
Interest expense (8,993,379) (5,522,783)
Loss on extinguishment of debt (9,962,495) 0
Gain on transfer of plasma center assets 11,527,421 0
Other expense (227,322) (127,121)
Other expense, net (6,854,990) (5,454,501)
NET LOSS $ (48,279,317) $ (65,743,445)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.89) $ (1.45)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted 54,348,136 45,188,899

Source